United Kingdom (UK)
Recombinant monoclonal antibody to Capsular antigen. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody P1E7.
Alternative Name(s) of Target: surface capsule antigen; Burkholderia mallei; BM; glanders; Burkholderia pseudomallei; BP; Burkholderia spp; melioidosis; Whitmore’s disease
Immunogen: The original antibody was generated by immunizing mice with various antigen preparations of B. pseudomallei (ATCC 23343). Later on phage display technique was used to generate scFv version of this antibody.
Specificity: This antibody binds surface capsular antigens of Burkholderia pseudomallei (BP), a causative agent of melioidosis, is a gram-negative, facultative anaerobic, motile bacillus commonly found in the soil and stagnant waters. BP infection is often due to either direct inoculation into wounds and skin abrasions or inhalation of contaminated materials. Recently, BP has been recognized as a major cause of community-acquired septicemia, resulting in significant mortality. This antibody also cross reacts with surface capsular antigens of Burkholderia mallei. B. mallei (BM), a host-adapted pathogen that does not normally persist in nature, causes glanders in horse. Some studies indicated that BM is highly infectious in humans by aerosol route.
Application Notes: This antibody can be used for the detection of capsular antigens of Burkholderia pseudomallei and Burkholderia mallei in a sample using ELISA. The binding affinity of the antibody against B. pseudomallei was measured (0.523 at OD405nm) (Kim et al., 2011; PMID: 21172353).
Antibody first published in:
Kim et al. Construction and molecular characterization of mouse single-chain variable fragment antibodies against Burkholderia mallei and Burkholderia pseudomallei. J Immunol Methods. 2011 Feb 28;365(1-2):101-9. PMID:21172353
Note on publication:
The paper describes the molecular characterization of scFv antibodies against Burkholderia mallei and Burkholderia pseudomallei generated using phage display technology.